[Clinicopathological study of oligodendroglioma with special reference to immunohistochemical investigation].
The present study was undertaken to evaluate the utility of pathologic features and specific immunohistochemical studies in estimating the prognosis of oligodendroglioma. The pathological diagnosis of an oligodendroglioma was made on HE stained-sections according to WHO classification. Sixteen oligodendrogliomas, twelve mixed oligoastrocytomas and ten anaplastic oligodendrogliomas were immunotested by the peroxidase-antiperoxidase (PAP) method with anti-GFAP serum, anti-S-100 serum and anti-MBP (Myelin basic protein) serum and by the avidin biotin peroxidase-complex (ABC) method with anti-vimentin serum and ant-Leu 7 monoclonal antibody. GFAP positive cells were interpreted as reactive astrocytes, neoplastic astrocytes and neoplastic oligodendrocytes, S-100 positive cells were interpreted as reactive astrocytes and neoplastic astrocytes. Leu 7 positive cells were found in only one case of anaplastic oligodendroglioma. Anti-Leu 7 could not be considered as a specific marker for oligodendroglioma. Of the anaplastic oligodendroglioma 60% displayed MBP positively and 70% displayed vimentin positively. NSE positive cells were found in a few anaplastic oligodendrogliomas. The present study has not so far uncovered any marker that is restricted to oligodendrogliomas. However GFAP may be useful to assess the extent of reactive astrocytes and neoplastic astrocytes in the oligodendroglioma or mixed oligoastrocytoma. MBP and vimentin will help to determine the malignancy of oligodendroglioma.
Kubo
O
O
Department of Neurosurgery, Tokyo Women's Medical College, Japan.
Tajika
Y
Y
Toyama
T
T
Tajika
T
T
Sakairi
M
M
Katahira
M
M
Kitamura
K
K
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000032:analysis* / Q000401:mortality / Q000473:pathology; D002648:Child; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D005910:Glioma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D004676:Myelin Basic Protein / Q000032:analysis; D009837:Oligodendroglioma / Q000032:analysis* / Q000401:mortality / Q000473:pathology; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D011379:Prognosis; D009418:S100 Proteins / Q000032:analysis; D014746:Vimentin / Q000032:analysis
D014408:Biomarkers, Tumor; D005904:Glial Fibrillary Acidic Protein; D004676:Myelin Basic Protein; D009418:S100 Proteins; D014746:Vimentin; D010751:Phosphopyruvate Hydratase